Categories: News

SANY Reports Strong First Half 2025 Results, Delivering Profitable Growth

Revenue Up 15% to $6.24 Billion; Operating Cash Flow Up 20% to $1.42 Billion

- Advertisement -

SHANGHAI, Aug. 28, 2025 /PRNewswire/ — On August 21, SANY Heavy Industry released its interim results for the first half of 2025. The company executed on its strategy of globalization, digitalization, and decarbonization, achieving balanced growth across scale, expansion, and profitability through continued product innovation and disciplined operations. Revenue reached $6.24 billion, a year-on-year increase of 14.96%; net income attributable to shareholders was $0.73 billion, up 46.00%; operating cash flow was $1.42 billion, an increase of 20.11%. Net income margin rebounded to 11.65%, up 2.50 p.p. compared to the same period last year. As of June 30, 2025, total assets stood at $21.54 billion, while net equity attributable to shareholders reached $10.30 billion.

- Advertisement -

Global Expansion and Continued Progress in Sustainability

- Advertisement -

In the first half of 2025, international revenue from the company’s core businesses reached $3.69 billion, up 11.72%, accounting for 60.26% of total revenue. Sales in the AsiaAustralia region rose 16.3% to $1.606 billion; Europe contributed $0.863 billion, up 0.66%; the Americas generated $0.71 billion, an increase of 1.36%; and Africa saw strong growth with revenue surging 40.48% to $0.509 billion

- Advertisement -

Benefiting from factors such as a more optimized product structure, SANY’s gross margin on international business reached 31.18% in the first half of 2025, an increase of 1.04 p.p. 

- Advertisement -

The company also accelerated its renewable energy initiatives, launching over 30 environmentally responsible products during the period and securing 30 authorized low-carbon patents on core components. The service life of reinforced slewing reducers GS23 and GS27 surpassed 15,000 hours. The successful introduction of the 100-ton excavator slewing reducer addressed a technology gap in the ultra-durable excavator reducer segment. 

- Advertisement -

Strengthening Core Businesses and R&D

- Advertisement -

SANY reported excavating machinery revenue of $2.45 billion, up 15.00% year-on-year. Revenue from concrete machinery reached $1.04 billion, down 6.49%, while hoisting machinery rose 17.89% to $1.09 billion. Piling machinery revenue increased 15.05% to $0.19 billion, and road machinery revenue surged 36.83% to $0.3 billion.

- Advertisement -

During the period, the company invested $0.3 billion in R&D and filed 246 patent applications (excluding software copyrights), of which 131 were invention patents.

- Advertisement -

Looking ahead, the company will continue to invest in innovation and modernizing operations, building a more resilient, competitive industry ecosystem while delivering sustainable growth and long-term value for shareholders. 

- Advertisement -

Photo – https://mma.prnewswire.com/media/2760216/image.jpg

- Advertisement -

Logo – https://mma.prnewswire.com/media/1518641/logo_Logo.jpg

- Advertisement -

 

- Advertisement -

 

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/sany-reports-strong-first-half-2025-results-delivering-profitable-growth-302541099.html

- Advertisement -

Recent Posts

CCTV+: Drums, Dragons, and Dynasty: 26th Qianlong Lantern Festival Ignites Living Heritage

BEIJING, March 4, 2026 /PRNewswire/ -- The Qianlong Lantern Festival, a premier Spring Festival tradition in northern…

16 minutes ago

For the Fourth Straight Year, Clarendelle & Domaine Clarence Dillon Will Bring Iconic Bordeaux Wines to Hollywood’s Biggest Night

As an Official Partner of the Academy, the prestigious family-owned company will exclusively pour red,…

16 minutes ago

Palladium Global Science Award 2026 opens submissions for new palladium applications

SHANGHAI, March 4, 2026 /PRNewswire/ -- The Palladium Global Science Award announced the launch of…

16 minutes ago

Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute

Study is Real-World Evaluation of the Clinical Utility of Sodium Thiosulfate Injection (PEDMARK®) in Reducing the…

3 hours ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Presented positive updated data from the ALLOHA™ Phase 1 heme trial at 67th American Society…

3 hours ago

Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026

Company to Host Conference Call at 8:30am ET March 04, 2026 07:00 ET  | Source:…

3 hours ago